Skip to main content
SpringerLink
Log in

Treatment of Serious Pseudomonas Aeruginosa Infections

North American Perspective

  • Chapter
Severe Infections Caused by Pseudomonas Aeruginosa

Part of the book series: Perspectives on Critical Care Infectious Diseases ((CCID,volume 7))

  • 272 Accesses

Abstract

Serious infections caused by Pseudomonas aeruginosa continue to be associated with high morbidity and mortality (1). Treatment options should be based upon in vitro susceptibility, clinical efficacy, likelihood of development of resistance, pharmacokinetic disposition and toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother 2002; 49(2):229–33.

    Article  PubMed  CAS  Google Scholar 

  2. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27(Suppl 1):S93–9.

    Article  PubMed  CAS  Google Scholar 

  3. Ramphal R, Hoban DJ, Pfaller MA, Jones RN. Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997–1998. Diagn Microbiol Infect Dis 2000; 36(2):125–9.

    Article  PubMed  CAS  Google Scholar 

  4. Livermore DM, Carter MW, Bagel S, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001; 45(6):1860–7.

    Article  PubMed  CAS  Google Scholar 

  5. Cavallo JD, Fabre R, Leblanc F, Nicolas-Chanoine MH, Thabaut A. Antibiotic susceptibility and mechanisms of beta-lactam resistance in 1310 strains of Pseudomonas aeruginosa: a french multicentre study(1996). J Antimicrob Chemother 2000; 46(1):133–6

    Article  PubMed  CAS  Google Scholar 

  6. Pfaller MA, Jones RN, Biedenbach DJ. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis 2001; 41(4):177–82.

    Article  PubMed  CAS  Google Scholar 

  7. Jones RN, Beach ML, Pfaller MA. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! Diagn Microbiol Infect Dis 2001; 41(3):161–3

    Article  PubMed  CAS  Google Scholar 

  8. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39(1):183–90.

    Article  PubMed  CAS  Google Scholar 

  9. Jones RN, Pfaller MA, Marshall SA, Hollis RJ, Wilke WW. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. Diagn Microbiol Infect Dis 1997; 29(3):187–92.

    Article  PubMed  CAS  Google Scholar 

  10. Liu PY, Lau YJ, Hu BS, et al. Comparison of susceptibility to extended-spectrum betalactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units. Diagn Microbiol Infect Dis 1995; 22(3):285–91.

    Article  PubMed  Google Scholar 

  11. Mathai D, Lewis MT, Kugler KC, Pfaller MA, Jones RN. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: 1--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagn Microbiol Infect Dis 2001; 39(2):105–16.

    Article  PubMed  CAS  Google Scholar 

  12. Chan-Tack KM. Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999. South Med J 2001; 94(6):619–20.

    PubMed  CAS  Google Scholar 

  13. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34(5):634–40.

    Article  PubMed  CAS  Google Scholar 

  14. Piddock LJ, Johnson M, Ricci V, Hill SL. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother 1998; 42(11):2956–60.

    PubMed  CAS  Google Scholar 

  15. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45(1):105–16.

    Article  PubMed  CAS  Google Scholar 

  16. Renau TE, Leger R, Yen R, et al. Peptidomimetics of Efflux Pump Inhibitors Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett 2002; 12(5):763–6.

    Article  PubMed  CAS  Google Scholar 

  17. Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999; 74(4):420–34.

    Article  PubMed  CAS  Google Scholar 

  18. Cambau E, Gutmann L. Mechanisms of resistance to quinolones. Drugs 1993; 45 Suppl3:15–23.

    Article  PubMed  CAS  Google Scholar 

  19. Karlowsky JA, Zelenitsky SA, Zhanel GG. Aminoglycoside adaptive resistance. Pharmacotherapy 1997; 17(3):549–55.

    PubMed  CAS  Google Scholar 

  20. Piddock Li. Mechanisms of fluoroquinolone resistance: an update 1994–1998. Drugs 1999; 58 Suppl2:11–8.

    Article  PubMed  CAS  Google Scholar 

  21. Jacoby GA, Archer GL. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med 1991; 324(9):601–12.

    Article  PubMed  CAS  Google Scholar 

  22. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33(9):960–7.

    Article  PubMed  CAS  Google Scholar 

  23. Bonfiglio G, Laksai Y, Franchino L, Amicosante G, Nicoletti G. Mechanisms of betalactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey. J Antimicrob Chemother 1998; 42(6):697–702.

    Article  PubMed  CAS  Google Scholar 

  24. Kucers A. “Gentamicin”. In The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 5th ed Kucers A, Crowe SM, Grayson ML, Hoy JF, eds. Oxford: Butterworth-Heinemann; 1997.

    Google Scholar 

  25. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25(5):1094–8.

    Article  PubMed  CAS  Google Scholar 

  26. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002; 34(3):340–5.

    Article  PubMed  Google Scholar 

  27. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43(6):1379–82.

    PubMed  CAS  Google Scholar 

  28. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47(3):247–50.

    Article  PubMed  CAS  Google Scholar 

  29. Boffi EI Amari E, Chamot E, Auckenthaler R, Pechere JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33(11):1859–64.

    Article  Google Scholar 

  30. Rybak MJ, McGrath BJ. Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician. Drugs 1996; 52(3):390–405.

    Article  PubMed  CAS  Google Scholar 

  31. Cappelletty DM, Rybak MJ. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40(3):677–83.

    PubMed  CAS  Google Scholar 

  32. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996; 40(8):1914–8.

    CAS  Google Scholar 

  33. Neu HC. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. Drugs 1993; 45 Suppl3:54–8.

    Article  PubMed  CAS  Google Scholar 

  34. Lister PD, Sanders WE, Jr., Sanders CC. Cefepime-aztreonam: a unique double betalactam combination for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42(7):1610–9.

    PubMed  CAS  Google Scholar 

  35. Graff LR, Franklin KK, Witt L, et al. Antimicrobial therapy of gram-negative bacteremia at two university-affiliated medical centers. Am J Med 2002; 112(3):204–11.

    Article  PubMed  Google Scholar 

  36. Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999; 27 Suppl 2:S24–8.

    Article  PubMed  Google Scholar 

  37. Hilf M, Yu VL, Sharp J, Zuravleff LT, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87(5):540–6.

    Article  PubMed  CAS  Google Scholar 

  38. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156(18):2121–6.

    Article  PubMed  CAS  Google Scholar 

  39. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000; 160(4):501–9.

    Article  CAS  Google Scholar 

  40. Leibovici L, Paul M, Poznanski 0, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41(5):1127–33.

    PubMed  CAS  Google Scholar 

  41. Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998; 2(4):211–5.

    Article  PubMed  CAS  Google Scholar 

  42. Guglielmo BJ “Principles of Infectious Diseases”. In. Applied Therapeutics: The Clinical Use of Drugs. 7th ed. Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, eds Baltimore: Lippincott Williams and Wilkins; 2001.

    Google Scholar 

  43. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992; 36(12):2577–83.

    Article  PubMed  CAS  Google Scholar 

  44. Crokaert F. Pharmacodynamics, a tool for a better use of antibiotics? Intensive Care Med 2001; 27(2):340–3.

    Article  PubMed  CAS  Google Scholar 

  45. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162(1):328–30.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of California, San Francisco, San Francisco, California, USA

    Pierre Voirol Ph.D. & B. Joseph Guglielmo Pharm.D.

Authors
  1. Pierre Voirol Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Joseph Guglielmo Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Microbiology/Immunology and Medicine, Northwestern University, Chicago, IL, USA

    Alan R. Hauser M.D., Ph.D.

  2. Critical Care Department, Joan XXIII University Hospital University Rovira & Virgili, Tarragona, Spain

    Jordi Rello M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Voirol, P., Guglielmo, B.J. (2003). Treatment of Serious Pseudomonas Aeruginosa Infections. In: Hauser, A.R., Rello, J. (eds) Severe Infections Caused by Pseudomonas Aeruginosa . Perspectives on Critical Care Infectious Diseases, vol 7. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0433-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0433-7_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5074-3

  • Online ISBN: 978-1-4615-0433-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation